ascendis pharma glp-1 receptor agonist weight management diabetes treatments Novo inks deal to develop long-acting GLP-1, other metabolic drugs Frontiers | GLP−1 receptor agonists
Description
Interestingly, many patients taking drugs such as Ozempic and Zepbound have reported similar experiences, saying their cravings for alcohol, cigarettes, or other substances decreased after starting treatment
Despite the lack of research on tirzepatide, especially in HF patients, its cardiovascular effects indicate potential benefits for this population
Omega-3 fatty acids (found in fish oil) have been investigated for various metabolic benefits
The GLP-1RA liraglutide has also been approved for the treatment of obesity at a higher standard dose (3 mg once daily) compared to the standard dose used for T2D treatment (1.2 mg once daily) due to the results of the SCALE study program (37, 38)
